Amferia AB

Amferia AB, based in Sweden, specializes in the development of innovative medical devices that utilize antimicrobial peptides to combat bacterial infections, contributing to healthcare solutions. Founded in 2018 in Molndal, Sweden, Amferia AB develops medical technologies focusing on antimicrobial solutions. The company has completed recent deal occurring in September 2025, when it raised EUR 3. 99 mn in venture funding.

Anand Rajasekharan and Saba Atefyekta are the co-founders, and Anand Rajasekharan serves as the CEO. Amferia specializes in the creation of advanced medical devices, particularly a peptide-hydrogel wound dressing that aims to restore the efficacy of antibiotics against drug-resistant bacteria. This product is currently utilized across eight European countries, serving healthcare providers, hospitals, and veterinary clinics. By mimicking natural immune responses, Amferia's products offer a non-toxic solution for infection management in human and veterinary medicine, while ongoing R&D efforts focus on expanding their product range and filing new patents.

The company generates income through direct sales of its medical solutions, specifically targeting hospitals and clinics internationally. Their business model is based on B2B transactions with healthcare entities, and although specific pricing details are not disclosed, fees are influenced by the unique advantages offered by Amferia's patented technologies. Amferia plans to utilize September 2025 to move its antimicrobial wound-care products through regulatory approval, expand sales of its animal-health products in Europe, and bring new peptide-based treatments to market.